BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54
LB Pharmaceuticals, Inc.
LB Pharmaceuticals, Inc. LBRX | 0.00 |
BMO Capital analyst Malcolm Hoffman maintains LB Pharmaceuticals (NASDAQ:
LBRX) with a Outperform and raises the price target from $46 to $54.